Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 nov. 2025 07h00 HE | Source: Sitryx Therapeutics

Sitryx presents new preclinical data highlighting PKM2 as a promising metabolic target for the treatment of atopic dermatitis at the Inflammatory Disease Skin Summit 2025

Preclinical data highlight that PKM2 modulation inhibits several important mechanisms underlying atopic dermatitis pathologySYX-5219 is a first-in-class oral PKM2 modulator designed to drive...
02 oct. 2025 07h00 HE | Source: Sitryx Therapeutics

Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseasesPhase 1b trial to investigate the safety, tolerability and initial...
10 avr. 2024 07h00 HE | Source: Sitryx Therapeutics

Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis

Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis First program from proprietary pipeline of novel immunometabolism-targeting therapies...